Trivitron Biocard Pro COVID-19 Antigen Rapid testing kits get ICMR nod
Advertisement
New Delhi: The Indian Council of Medical Research (ICMR) has granted its approval to Trivitron Healthcare Private Limited, a medical technology company to commercially launch their flagship product COVID-19 Rapid Testing Antigen Kit.
This Covid-19 testing kits will be branded as 'Biocard Pro COVID-19 Rapid Antigen' and is claimed to provide accurate results in just 7~10 minutes.
Individuals suspected to have been infected with the novel coronavirus (nCoV) can make use of the Biocard Pro COVID-19 Rapid Antigen kit to confirm their infection status. Biocard Pro COVID-19 Rapid Antigen kit is a chromatographic immunoassay for the qualitative detection of COVID-19 specific antigen present in human nasopharyngeal. Using a nasal swab to get a fluid sample, antigen tests can produce results in minutes. As these tests are faster and less expensive than other popularly done PCR tests, antigen tests may be more practical to use for large numbers of people.
Technical Specification of Biocard Pro COVID-19 Rapid Ag test kit:
Method: Immuno chromatography
Sample type: Nasopharyngeal Swab
Assay Time: 7 to 10 minutes
Storage: 4 to 30 ◦ C
Shelf-life: 24 months
Mr. Rajesh Patel, Chief Executive Officer – IVD India, Trivitron Healthcare, on this occasion said - The main focus is to contribute in the global fight against COVID-19 through world class products and expertise in medical technology. Our Rapid antigen test is quicker than the available RTPCR based tests, as it takes approximately 7-10 minutes, compared to about five hours being taken by the RT- PCR based testing methods. Also, confirmation through antigen based tests does not require a sophisticated laboratory, which is a key requirement for RT-PCR tests.
Till date, more than 25 antigen-based rapid test kits that have been validated and only few kits have been found to yield satisfactory results and Trivitron's Biocard Pro is one of these few.
Biocard Pro COVID-19 Rapid Antigen kit will be manufactured at Trivitron's Chennai manufacturing facility at the rate of around 4.5-5 million tests per month. The company plans to distribute these kits to various government entities and private laboratories through various marketing channels.
Read also: Rajesh Patel appointed as CEO of Trivitron Healthcare India IVD business
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.